Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.750
-0.020 (-1.13%)
May 29, 2026, 2:49 PM EDT - Market open
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $298.24 million as of May 29, 2026. Its market cap has increased by 48.59% in one year.
Market Cap
298.24M
Enterprise Value
130.43M
1-Year Change
48.59%
Ranking
Category
Stock Price
$1.75
Market Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $298.24M, an increase of 196.88%. That is a compound annual growth rate of 22.19%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 28, 2026 | 301.65M | 7.58% |
| Dec 31, 2025 | 280.40M | -3.25% |
| Dec 31, 2024 | 289.83M | 3,596.14% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 23, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Immuneering | 327.37M |
| Bicycle Therapeutics | 326.02M |
| Silence Therapeutics | 324.03M |
| Fate Therapeutics | 306.55M |
| Niagen Bioscience | 306.48M |
| Surrozen | 304.89M |
| Opus Genetics | 299.89M |
| Eledon Pharmaceuticals | 299.16M |